FDA approves Zanvastro as first treatment for Alexander disease
The FDA has approved Zanvastro as the first treatment for Alexander disease in paediatric and adult patients.
Zanvastro, also known as zilganersen, is the first FDA-approved therapy for Alexander disease and the first treatment designed to directly address the GFAP protein accumulation that drives the rare neurological disorder.
The approval introduces a disease-targeted treatment for patients who previously had no approved therapeutic option beyond supportive care.
Field | Content |
Alert Type | Approval |
Drug Name | Zilganersen |
Brand Name | Zanvastro |
Company | Ionis Pharmaceuticals |
Regulatory Authority | U.S. Food and Drug Administration |
Approval Type | New drug approval |
Indication | Treatment of Alexander disease in paediatric and adult patients |
Therapy Area(s) | Neurology; rare disease |
Geography | United States |
What Happened | The FDA approved Zanvastro (zilganersen) for the treatment of Alexander disease in paediatric and adult patients. |
Why It Matters | Zanvastro is the first FDA-approved treatment for Alexander disease and the first therapy designed to directly target the underlying protein accumulation driving the disorder. |
Supporting Context | Alexander disease is a rare progressive neurological disorder caused by mutations affecting glial fibrillary acidic protein, or GFAP. |
Key Takeaway | FDA approval of Zanvastro establishes the first disease-targeted treatment option for people with Alexander disease. |
What to Watch | Clinical adoption of Zanvastro and longer-term evidence on its impact across paediatric and adult Alexander disease populations. |
Primary Source | U.S. Food and Drug Administration |
Relevant Date | 3 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글